Daiichi Sankyo To Submit NDA For Edoxaban In 2010
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo Dec. 11 announced a plan to submit an NDA for oral factor Xa inhibitor edoxaban (Du-176b) to prevent venous thromboembolism in Japan